|
|
|
|
| |
|
|
| Holzmann,Iandra; Tovo,Cristiane V.; Minmé,Roseline; Leal,Mônica P.; Kliemann,Michele P.; Ubirajara,Camila; Aquino,Amanda A.; Araujo,Bruna; Almeida,Paulo R.L.. |
| ABSTRACT Introduction Chronic hepatitis C virus infection is one of the major causes of cirrhosis, hepatocellular carcinoma and liver transplantation. Treatment using direct-acting antivirals has revolutionized the treatment of hepatitis C virus, increasing long-term prognosis after cure. The goal of the present study was to evaluate the effectiveness of direct-acting antivirals in a Public Health System in southern Brazil. Methods A retrospective study evaluated all patients with chronic hepatitis C virus infection who underwent treatment at one center of the Public Health Department of the State of Rio Grande do Sul - Brazil, according to the Brazilian Clinical Protocol and Therapeutic Guidelines. The effectiveness was assessed in terms sustained... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Sofosbuvir; Daclatasvir; Simeprevir; DAA; Sustained virological response. |
| Ano: 2018 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702018000400317 |
| |
|
|
| Zanaga,L.P.; Miotto,N.; Mendes,L.C.; Stucchi,R.S.B.; Vigani,A.G.. |
| Hepatitis C virus (HCV) genotype 3 is responsible for 30.1% of chronic hepatitis C infection cases worldwide. In the era of direct-acting antivirals, these patients have become one of the most challenging to treat, due to fewer effective drug options, higher risk of developing cirrhosis and hepatocellular carcinoma and lower sustained virological response (SVR) rates. Currently there are 4 recommended drugs for the treatment of HCV genotype 3: pegylated interferon (PegIFN), sofosbuvir (SOF), daclatasvir (DCV) and ribavirin (RBV). Treatment with PegIFN, SOF and RBV for 12 weeks has an overall SVR rate of 83–100%, without significant differences among cirrhotic and non-cirrhotic patients. However, this therapeutic regimen has several contraindications and... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatitis C treatment; Genotype 3; Sofosbuvir; Daclatasvir; Ribavirin. |
| Ano: 2016 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016001100302 |
| |
|
|
| Zanaga,L.P.; Santos,A.G.; Ataíde,E.C.; Boin,I.F.S.F.; Stucchi,R.S.B.. |
| Recurrent hepatitis C (HCV) after liver transplantation (LT) is an important cause of morbidity and mortality. Antiviral treatment is recommended to avoid unfavorable outcomes. Direct-acting antivirals (DAA) have transformed HCV treatment, with higher efficacy and fewer side-effects than interferon-based therapies traditionally used. To evaluate DAA treatment outcomes at a Brazilian transplant unit, data of patients who finished HCV treatment at the Liver Transplant Unit of the University of Campinas were analyzed. Treatment consisted of sofosbuvir, daclatasvir, and ribavirin, for 12 or 24 weeks, according to the national guidelines. Fifty-five patients completed antiviral treatment and 54 had HCV-viral load results available. The majority of patients were... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatitis C; Liver transplantation; Direct acting antivirals; Sofosbuvir; Daclatasvir; Recurrent hepatitis. |
| Ano: 2019 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2019000800606 |
| |
|
|
|
